Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Laboratory Block, University of Hong Kong, 2/F, 21 Sassoon Road, Hong Kong Special Administrative Region, China.
Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):553-561. doi: 10.1007/s10096-018-03459-x. Epub 2019 Jan 25.
Up-to-date data on the burden of disease are important to identify patients with unmet needs and to optimize healthcare resources. We aimed to characterize the burden of pneumonia hospitalizations in Hong Kong and inform targeted healthcare policies for pneumonia control in the era of global aging. This was a population-based study using a territory-wide administrative electronic health record system that covers all public hospitals of Hong Kong. Patients admitted to public hospitals, from 2011 to 2015, with a diagnosis of pneumonia at discharge were identified based on the International Classification of Diseases-Ninth Revision-Clinical Modification Codes (480-486 and 487.0). Incidence, inpatient case-fatality, all-cause fatality, 28-day readmission, hospital length of stay, and healthcare costs were assessed for seven age strata. We identified 323,992 patients (median age 80 years, 44.4% female) with hospitalized pneumonia (organism unspecified 84.2%; bacterial pneumonia 12.3%; viral pneumonia 2.5%; others 1.0%). Annual incidence was 955.1 per 100,000 population, with a 10.6% decrease from 2011 to 2015. Case-fatality, all-cause fatality, and 28-days readmission risks were 13.8, 21.6, and 19.5%, respectively. The average hospital length of stay was 14.1 days with corresponding direct costs of $9348 USD per episode in the monetary value of 2015. Individuals aged ≥ 65 years accounted for over 75% of pneumonia-related hospitalizations, 90% of deaths, and the majority of healthcare costs. Hospitalized pneumonia represents a considerable health and economic burden in Hong Kong, especially in older adults. The study provides a population-level baseline estimate for further cost-effective evaluation of targeted strategies for pneumonia control.
最新的疾病负担数据对于识别未满足需求的患者和优化医疗资源至关重要。本研究旨在描述香港肺炎住院患者的疾病负担,并为老龄化社会时代的肺炎防控提供有针对性的卫生政策建议。本研究采用基于人群的方法,利用香港全地域行政电子健康记录系统,覆盖了所有公立医院。该系统基于国际疾病分类第 9 版临床修订版代码(480-486 和 487.0),确定了 2011 年至 2015 年期间因肺炎出院的住院患者。评估了七个年龄组的发病率、住院病死率、全因病死率、28 天再入院率、住院时间和医疗费用。共确定了 323992 例(中位年龄 80 岁,44.4%为女性)患有住院肺炎(病原体不明 84.2%;细菌性肺炎 12.3%;病毒性肺炎 2.5%;其他肺炎 1.0%)。肺炎发病率为 955.1/10 万人,2011 年至 2015 年期间下降了 10.6%。病死率、全因病死率和 28 天再入院率分别为 13.8%、21.6%和 19.5%。平均住院时间为 14.1 天,2015 年的每个病例直接费用为 9348 美元。≥65 岁的患者占肺炎相关住院患者的 75%以上,占死亡人数的 90%,占医疗费用的大部分。在香港,肺炎住院患者给卫生系统带来了巨大的健康和经济负担,尤其是对老年人而言。本研究为进一步评估针对肺炎防控的具有成本效益的目标策略提供了人群水平的基线估计。